Cybrexa Therapeutics

Cybrexa Therapeutics

Cybrexa Therapeutics

Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
Type
B2c
Founded
2017
Raised
$6M
Follow us
Alexa global traffic share
Latest funding
$6,000,000
Venture capital (Series B) - 2017
Connecticut Innovations HighCape Partners
Team Size
2
Employees
$6,000,000 Venture capital (Series B)
FinSMEs , PE HUB

Cybrexa Therapeutics Raises $6M in Series B Financing